Positron emission tomography an imaging biomarker in pulmonary fibrosis: from therapeutic mechanism to treatment monitoring.
作者信息
Cho Sang-Geon, Herzog Erica L, Thorn Stephanie L, Sinusas Albert J
机构信息
Department of Nuclear Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea; Yale Translational Research Imaging Center, Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, CT, USA.
Departments of Medicine and Pathology, Yale School of Medicine, Yale University, New Haven, CT, USA.
出版信息
EBioMedicine. 2025 Jan;111:105519. doi: 10.1016/j.ebiom.2024.105519. Epub 2024 Dec 18.
Abstract
摘要
相似文献
1
Positron emission tomography an imaging biomarker in pulmonary fibrosis: from therapeutic mechanism to treatment monitoring.正电子发射断层扫描：肺纤维化中的一种成像生物标志物——从治疗机制到治疗监测
EBioMedicine. 2025 Jan;111:105519. doi: 10.1016/j.ebiom.2024.105519. Epub 2024 Dec 18.
2
Imaging Pulmonary Fibrosis and Treatment Efficacy In Vivo with Autotaxin-Specific PET Ligand [F]ATX-1905.用自主分泌酶特异性 PET 配体 [F]ATX-1905 进行肺纤维化的体内成像和治疗效果评估。
Mol Pharm. 2024 Oct 7;21(10):5171-5181. doi: 10.1021/acs.molpharmaceut.4c00571. Epub 2024 Aug 26.
3
Platelet-derived growth factor receptor β-targeted positron emission tomography imaging for the noninvasive monitoring of liver fibrosis.血小板衍生生长因子受体 β 靶向正电子发射断层扫描成像用于肝纤维化的无创监测。
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1530-1543. doi: 10.1007/s00259-023-06577-7. Epub 2024 Jan 8.
4
Molecular imaging in experimental pulmonary fibrosis reveals that nintedanib unexpectedly modulates CCR2 immune cell infiltration.实验性肺纤维化中的分子成像显示，尼达尼布意外地调节了CCR2免疫细胞浸润。
EBioMedicine. 2024 Dec;110:105431. doi: 10.1016/j.ebiom.2024.105431. Epub 2024 Nov 7.
5
2020 American Thoracic Society BEAR Cage Winning Proposal: Collagen-targeted Positron Emission Tomography Imaging as a Novel Biomarker of Treatment Response in Idiopathic Pulmonary Fibrosis.2020年美国胸科学会BEAR奖获奖提案：以胶原蛋白为靶点的正电子发射断层扫描成像作为特发性肺纤维化治疗反应的新型生物标志物
Am J Respir Crit Care Med. 2021 May 1;203(9):1065-1067. doi: 10.1164/rccm.202010-3994ED.
6
[F]AlF-CBP imaging of type I collagen for non-invasive monitoring of pulmonary fibrosis in preclinical models.利用 AlF-CBP 对 I 型胶原进行成像，以实现对临床前模型中肺纤维化的非侵入性监测。
Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):22-35. doi: 10.1007/s00259-024-06888-3. Epub 2024 Aug 22.
7
[Ga]FAPI PET for Imaging and Treatment Monitoring in a Preclinical Model of Pulmonary Fibrosis: Comparison to [F]FDG PET and CT.[镓]FAPI PET用于肺纤维化临床前模型的成像和治疗监测：与[氟]FDG PET及CT的比较
Pharmaceuticals (Basel). 2024 Jun 3;17(6):726. doi: 10.3390/ph17060726.
8
[ Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity.镓（Ga）-FAPI-46 PET 用于非侵入性检测肺纤维化疾病活动度。
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3705-3716. doi: 10.1007/s00259-022-05814-9. Epub 2022 May 12.
9
Positron emission tomography and computed tomography versus positron emission tomography computed tomography: tools for imaging the lung.正电子发射断层扫描与计算机断层扫描对比正电子发射断层扫描计算机断层扫描：肺部成像工具
Proc Am Thorac Soc. 2007 Aug 1;4(4):328-33. doi: 10.1513/pats.200611-173HT.
10
3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung.3'-脱氧-3'-[18F]氟代胸苷正电子发射断层扫描描绘特发性肺动脉高压患者肺中的异质性增殖病理学。
Circ Cardiovasc Imaging. 2018 Aug;11(8):e007402. doi: 10.1161/CIRCIMAGING.117.007402.
本文引用的文献
1
Molecular imaging in experimental pulmonary fibrosis reveals that nintedanib unexpectedly modulates CCR2 immune cell infiltration.实验性肺纤维化中的分子成像显示，尼达尼布意外地调节了CCR2免疫细胞浸润。
EBioMedicine. 2024 Dec;110:105431. doi: 10.1016/j.ebiom.2024.105431. Epub 2024 Nov 7.
2
Development of a CCR2 targeted F-labeled radiotracer for atherosclerosis imaging with PET.开发一种用于正电子发射断层扫描（PET）动脉粥样硬化成像的靶向CCR2的F标记放射性示踪剂。
Nucl Med Biol. 2024 Mar-Apr;130-131:108893. doi: 10.1016/j.nucmedbio.2024.108893. Epub 2024 Feb 23.
3
Initial results with [F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis.[F]FAPI-74 PET/CT在特发性肺纤维化中的初步结果。
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1605-1611. doi: 10.1007/s00259-023-06564-y. Epub 2023 Dec 20.
4
Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis.抗纤维化药物治疗 CTD-ILD 和 RA-ILD 的疗效和安全性：系统评价和荟萃分析。
Respir Med. 2023 Sep;216:107329. doi: 10.1016/j.rmed.2023.107329. Epub 2023 Jun 12.
5
Scale down and optimized automated production of [68Ga]68Ga-DOTA-ECL1i PET tracer targeting CCR2 expression.缩小规模并优化针对CCR2表达的[68Ga]68Ga-DOTA-ECL1i PET示踪剂的自动化生产。
EJNMMI Radiopharm Chem. 2023 Feb 2;8(1):3. doi: 10.1186/s41181-023-00188-1.
6
Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases.间质性肺疾病成纤维细胞激活蛋白表达的综合分析。
Am J Respir Crit Care Med. 2023 Jan 15;207(2):160-172. doi: 10.1164/rccm.202110-2414OC.
7
Chemokine Receptor 2-targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial.趋化因子受体 2 靶向分子成像在肺纤维化中的应用。一项临床试验。
Am J Respir Crit Care Med. 2021 Jan 1;203(1):78-89. doi: 10.1164/rccm.202004-1132OC.
8
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.CC 趋化因子配体 2 抑制特发性肺纤维化：卡鲁单抗的 2 期临床试验。
Eur Respir J. 2015 Dec;46(6):1740-50. doi: 10.1183/13993003.01558-2014. Epub 2015 Oct 22.
Zotero 插件